JDRF provides seed funding for highly innovative research with significant potential to accelerate the most promising type 1 diabetes (T1D) research in both cures and approaches to improve disease management. JDRF Innovation Grants address key challenges in T1D research and have the potential to generate ground-breaking discoveries. JDRF is thrilled to announce that two Canadian […]
In late April 2023, Helena Gottschling was elected Board Chair for JDRF Canada. Helena Gottschling is a purpose-driven leader who enjoyed a 37-year career with RBC before retiring in 2022. As Chief Human Resources Officer (CHRO) from 2017-2022, Helena was a member of Group Executive who set the overall strategic direction of RBC, Canada’s biggest […]
Mental health and psychosocial issues remain an under-researched yet frequent aspect of living with type 1 diabetes (T1D). As part of the JDRF-CIHR Partnership to Defeat Diabetes, JDRF is pleased to support four new Canadian grants focused on improving mental health and wellness in people with T1D. These grants are each worth $1 million over […]
May is Mental Health Awareness month, a national movement to raise awareness of the importance of mental health, and the structural gaps that exist in accessing treatment and support. There is no physical health without mental health, and this truth is beginning to be woven into a holistic approach to health care. JDRF has long […]
JDRF Canada and all JDRF affiliates are committed to supporting the development of cell replacement therapies that will one day offer cures for type 1 diabetes (T1D). T1D is an autoimmune disease where the body attacks and kills off the cells in the pancreas responsible for producing insulin. The first step in the cell replacement […]
In addition to funding critical type 1 diabetes (T1D) clinical trials, a key focus for JDRF is increasing awareness of and participation in trials. All new interventions, from drugs to devices to programs like mental health and peer support, must undergo clinical trials before they can be applied in everyday practice and benefit the people […]
Receiving a diagnosis of type 1 diabetes (T1D) for their child can be overwhelming for a family. And it was no different for Tienne and Andreas Schaub, when on April 4th 2022, they learned their daughter Leia had T1D. To honour Leia’s first year ‘diaversary’ (anniversary of her T1D diagnosis date) the family has put […]
Launched in 2017, the JDRF-CIHR Partnership to Defeat Diabetes is a landmark collaboration between the Government of Canada, through the Canadian Institute of Health Research (CIHR) and JDRF Canada for a total combined investment of $30 million to support transformative type 1 diabetes (T1D) research. This Partnership was renewed for a further $30 million through […]
Wednesday, March 8 is International Women’s Day (IWD), recognized around the world. IWD asks us to imagine a gender equal world. One that is free from bias, stereotypes, and discrimination. A world that’s diverse, equitable, and inclusive. A world where difference is valued and celebrated. The theme for 2023 is #EmbraceEquity and calls upon us […]
A new JDRF International-funded study of a drug called verapamil is offering exciting new potential for a path to keeping beta cells healthier for longer in people with type 1 diabetes (T1D).When a person is diagnosed with T1D, they still have some remaining beta cells that continue to insulin for a few months – known […]
The causes of type 1 diabetes (T1D) are complex and not fully understood. What is known is that there is a genetic component to developing T1D – but who is at greater risk? JDRF Canada is pleased to announce a new JDRF grant to support Dr. Despoina Manousaki, pediatric endocrinologist and genetic epidemiologist at Sainte-Justine […]
A significant part of JDRF Canada’s research strategy is funding the most promising cure-based research for type 1 diabetes (T1D). T1D is an autoimmune disease where the body destroys the cells in the pancreas responsible for making insulin. People with T1D must administer external sources of insulin, either through multiple daily injections, pump or pen […]
